Table 3.

Independent prognostic factors for progression-free survival (PFS).

Characteristics		Univariate analysis			Multivariate analysis
		HR	95%CI	P	HR	95%	P
Age	≤60 years	Reference		0.960			NI
	>60 years	1.010	0.674–1.514
Gender	Male	Reference		0.192			NI
	Female	1.311	0.873–1.968
WBC (*109)	≤10	Reference		0.003	Reference
	>10	2.904	1.445–5.835		3.016	0.950–6.274	0.065
HGB (g/L)	≤120	Reference		0.732			NI
	>120	0.930	0.615–1.407
PLT (*109)	≤100	Reference		0.949			NI
	>100	1.016	0.622–1.659
ALT (U/L)	≤40	Reference		0.617			NI
	>40	1.109	0.739–1.665
AST (U/L)	≤40	Reference		0.685			NI
	>40	0.917	0.603–1.395
ALP (U/L)	≤100	Reference		0.950			NI
	>100	1.013	0.676–1.518
GGT (U/L)	≤45	Reference					NI
	>45	0.885	0.591–1.326	0.555
ALB (g/L)	≤40	Reference					NI
	>40	0.857	0.541–1.357	0.510
TBIL (umol/L)	≤20.5	Reference					NI
	>20.5	0.869	0.575–1.314	0.506
IBIL (umol/L)	≤15	Reference					NI
	>15	1.130	0.688–1.857	0.629
CRP (ng/L)	≤3	Reference					NI
	>3	1.141	0.760–1.714	0.524
CEA (ng/mL)	≤5	Reference		0.645			NI
	>5	1.100	0.734–1.647
CA19-9 (U/ml)	≤35	Reference		0.060			NI
	>35	1.623	0.979–2.689
Tumor size	≤2	Reference		0.049	Reference
	2~4	1.719	1.004–2.945		1.429	0.801–2.550	0.227
0.227	>4	2.065	1.185–3.598	0.010	1.213	0.622–2.366	0.571
Tumor site	Head	Reference					NI
	Body/Tail	1.093	0.799–1.494	0.578
Treatment	Chemotherapy	Reference			Reference
	Conversional surgery	0.530	0.303–0.927	0.026	0.562	0.303–1.044	0.068
	Chemotherapy + IRE	0.446	0.261–0.761	0.003	0.529	1.169–0.279	0.042
Chemotherapy type	S-1	Reference					NI
	AG	0.635	0.328–1.227	0.176
	FOLFIRINOX	0.751	0.452–1.248	0.269
Imaging LN metastasis	Absence	Reference			Reference
	Present	1.879	1.228–2.873	0.004	1.502	0.929–2.428	0.097
HBsAg	No	Reference					NI
	Yes	0.708	0.327–1.532	0.380

PFS, progression free survival, other abbreviations as in Table 1 .